Replimune Group, Inc. (REPL)
NASDAQ: REPL · Real-Time Price · USD
4.910
-0.310 (-5.94%)
At close: May 22, 2026, 4:00 PM EDT
4.915
+0.005 (0.11%)
After-hours: May 22, 2026, 7:46 PM EDT
Replimune Group Employees
Replimune Group had 479 employees as of March 31, 2025. The number of employees increased by 148 or 44.71% compared to the previous year.
Employees
479
Change (1Y)
148
Growth (1Y)
44.71%
Revenue / Employee
n/a
Profits / Employee
-$657,313
Market Cap
405.43M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 479 | 148 | 44.71% |
| Mar 31, 2024 | 331 | 47 | 16.55% |
| Mar 31, 2023 | 284 | 78 | 37.86% |
| Mar 31, 2022 | 206 | 54 | 35.53% |
| Mar 31, 2021 | 152 | 30 | 24.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyell Immunopharma | 161 |
| Sutro Biopharma | 137 |
| Enanta Pharmaceuticals | 120 |
| C4 Therapeutics | 104 |
| Century Therapeutics | 78 |
| Lexeo Therapeutics | 59 |
| Zura Bio | 40 |
| vTv Therapeutics | 26 |
REPL News
- 5 days ago - Replimune Group call volume above normal and directionally bullish - TheFly
- 17 days ago - Replimune jumps on news FDA chief behind RP1 rejection may be removed - TheFly
- 20 days ago - FDA Commissioner Makary defends agency's decision on Replimune's drug - Reuters
- 4 weeks ago - US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection - Reuters
- 4 weeks ago - Replimune rises after Wall Street Journal editorial defending RP1 - TheFly
- 6 weeks ago - Replimune downgraded to Neutral from Outperform at Wedbush - TheFly
- 6 weeks ago - Replimune downgraded to Market Perform from Outperform at Leerink - TheFly
- 6 weeks ago - Replimune downgraded to Sell from Buy at H.C. Wainwright - TheFly